Fast Facts Myeloproliferative Neoplasms

Download Fast Facts Myeloproliferative Neoplasms full books in PDF, epub, and Kindle. Read online free Fast Facts Myeloproliferative Neoplasms ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!

Fast Facts: Myeloproliferative Neoplasms

Fast Facts: Myeloproliferative Neoplasms
Author :
Publisher : Karger Medical and Scientific Publishers
Total Pages : 117
Release :
ISBN-10 : 9781910797808
ISBN-13 : 1910797804
Rating : 4/5 (804 Downloads)

Book Synopsis Fast Facts: Myeloproliferative Neoplasms by : R.A. Mesa

Download or read book Fast Facts: Myeloproliferative Neoplasms written by R.A. Mesa and published by Karger Medical and Scientific Publishers. This book was released on 2019-02-11 with total page 117 pages. Available in PDF, EPUB and Kindle. Book excerpt: Presentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as understanding of the underlying molecular basis for these disorders emerges. Appropriate management is increasingly informed by accurate risk stratification founded on understanding of cytogenetic and molecular markers, as well as the clinical presentation. 'Fast Facts: myeloproliferative neoplasms' focuses on the three most common chronic MPNs: • Essential thrombocythemia (ET) – characterized by increased platelet count • Polycythemia vera (PV) – characterized by excessive production of red blood cells • Primary myelofibrosis – a more severe and heterogenous disorder that may overlap with ET and PV but is commonly associated with anemia. Written by two leading experts in the field, Fast Facts: myeloproliferative neoplasms provides concise, up-to-date and practical guidance on the accurate diagnosis, risk stratification and management of these MPNs. It also provides key insights into our growing understanding of the underlying molecular and genetic basis of these disorders, and how this is informing risk stratification and management strategies. This concise handbook will be invaluable to clinicians, medical students, nurses, pharmacists and scientists in understanding and overcoming the everyday and rarer challenges associated with MPN.


Fast Facts: Myeloproliferative Neoplasms Related Books

Fast Facts: Myeloproliferative Neoplasms
Language: en
Pages: 117
Authors: R.A. Mesa
Categories: Medical
Type: BOOK - Published: 2019-02-11 - Publisher: Karger Medical and Scientific Publishers

DOWNLOAD EBOOK

Presentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as
Fast Facts: Myeloproliferative Neoplasms
Language: en
Pages: 117
Authors: Ruben A. Mesa
Categories: Medical
Type: BOOK - Published: 2019 - Publisher: Karger Medical and Scientific Publishers

DOWNLOAD EBOOK

Presentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as
Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm
Language: en
Pages: 54
Authors: Eric Deconinck
Categories: Medical
Type: BOOK - Published: 2021-02-12 - Publisher: Karger Medical and Scientific Publishers

DOWNLOAD EBOOK

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare fast-growing hematodermic neoplasm that most often occurs in older men. It is notable for its hig
Fast Facts: Myelofibrosis
Language: en
Pages: 102
Authors: Donal McLornan
Categories: Medical
Type: BOOK - Published: 2022-04-25 - Publisher: Karger Medical and Scientific Publishers

DOWNLOAD EBOOK

Myelofibrosis is a myeloproliferative neoplasm that has markedly heterogeneous features. The clinical phenotype can range from initial indolent presentation, wh
Fast Facts: Acute Myeloid Leukemia
Language: en
Pages: 90
Authors: William Blum
Categories: Medical
Type: BOOK - Published: 2018-05-14 - Publisher: Karger Medical and Scientific Publishers

DOWNLOAD EBOOK

This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor p